Novasenta Completes $40 Million Series A To Advance Novel Cancer Therapeutics

Jul 29, 2022•over 3 years ago

Amount Raised

$40 Million

Round Type

series a

PittsburghBiotechnology

Description

Novasenta Inc., a startup biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, today announced the completion of $40 million in Series A financing led by UPMC Enterprises, the innovation, venture capital and commercialization arm of leading health system UPMC. The funding will allow Novasenta to advance its pipeline of antibody-based therapeutics and expand its proprietary computational platforms for target discovery, while continuing to recruit top talent.

Company Information

Company

Novasenta Inc.

Location

350 TECHNOLOGY DRIVE

Pittsburgh, Pennsylvania, United States

About

Novasenta discovers novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer. We use systematic, rigorous, and unbiased human tumor microenvironment analysis to uncover new druggable targets, exploiting the critical interplay of disease, immune response, and metabolism. Single-cell level analysis of high-quality, human tumor samples combined with the advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient. Our goal is to identify novel targets to generate effective therapies for a range of cancers.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Novasenta Completes $40 Million Series A To Advance Novel Cancer Therapeutics

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information